425: Alumis to Merge with ACELYRIN Following Year-End 2024 Financial Results

Alumis Inc. announces a merger agreement with ACELYRIN, along with its year-end 2024 financial results and clinical development updates.

Summary

• Alumis Inc. reported its year-end 2024 financial results and highlighted recent achievements, including the presentation of Phase 2 STRIDE OLE data for ESK-001 and Phase 1 data for A-005.
• The company announced a merger agreement with ACELYRIN, expected to close in the second quarter of 2025, creating a combined entity with a strong balance sheet and a differentiated late-stage portfolio.
• Alumis' cash, cash equivalents, and marketable securities totaled $288.3 million as of December 31, 2024.
• Research and development expenses for 2024 were $265.6 million, compared to $137.7 million in 2023.
• General and administrative expenses increased to $35.2 million in 2024 from $20.5 million in 2023.
• The net loss for 2024 was $294.2 million, compared to $155.0 million in 2023.
• The combined company is expected to have a cash runway into 2027, with a pro forma cash position of approximately $737 million as of December 31, 2024.
• Alumis stockholders will own approximately 55% of the combined company, while ACELYRIN stockholders will own approximately 45% on a fully diluted basis.

Sentiment

Score: 7

Explanation: The document presents a positive outlook due to the merger announcement and pipeline advancements, but the increased net loss tempers the overall sentiment.

Positives

• ESK-001 demonstrated sustained clinical responses and a favorable safety profile in Phase 2 trials for psoriasis.
• A-005 showed the ability to cross the blood-brain barrier in Phase 1 trials, supporting its potential for treating multiple sclerosis.
• The merger with ACELYRIN is expected to create a leading immunology and inflammation company with multiple upcoming development milestones.
• The combined company's cash position is expected to provide a runway into 2027.
• Key leadership appointments have been made to support the transition to a late-stage company.

Negatives

• Alumis reported a significant net loss of $294.2 million for the year ended December 31, 2024, compared to $155.0 million in 2023.
• Research and development expenses increased substantially, driven by clinical milestone payments and increased trial costs.

Risks

• The merger with ACELYRIN is subject to stockholder approval and customary closing conditions.
• Delays in clinical trial timelines could impact the company's development milestones, with Phase 3 ONWARD program data readout for ESK-001 in psoriasis now expected in the first quarter of 2026.
• The company faces risks associated with advancing clinical candidates, obtaining regulatory approval, and commercializing products.
• There are risks related to protecting intellectual property and potential claims of infringement.
• The company's future performance is subject to economic, business, and competitive factors.

Future Outlook

Alumis anticipates the merger with ACELYRIN will close in the second quarter of 2025 and expects the combined company's cash position to provide a runway into 2027. The company plans to advance its pipeline, including ESK-001 and A-005, through key data readouts and clinical trials.

Management Comments

• Martin Babler, President and Chief Executive Officer of Alumis, stated that the next 12-18 months will bring major milestones for Alumis.
• Babler added that the merger agreement with ACELYRIN represents a significant step forward in Alumis' strategic progress.

Industry Context

The merger between Alumis and ACELYRIN reflects a trend in the biopharmaceutical industry towards consolidation to create companies with stronger financial positions and more diversified pipelines. This allows for greater efficiency in drug development and commercialization, particularly in the competitive immunology and inflammation space.

Comparison to Industry Standards

• Alumis' focus on oral TYK2 inhibitors aligns with the industry's shift towards more convenient and patient-friendly drug delivery methods.
• The company's pipeline targets immune-mediated diseases, a market with significant unmet needs and substantial growth potential.
• The pro forma cash position of $737 million is competitive with other late-stage biopharmaceutical companies, providing financial flexibility to advance clinical programs.
• Comparable companies in the TYK2 inhibitor space include Bristol Myers Squibb (Deucravacitinib) and Takeda (potential competitors in the immunology space).

Management Changes

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger, with Alumis stockholders owning approximately 55% and ACELYRIN stockholders owning approximately 45% of the combined company.
• Employees of both companies may experience changes as a result of the merger, including potential restructuring and integration efforts.
• Patients with immune-mediated diseases could benefit from the combined company's pipeline of therapies.
• The merger is expected to provide increased financial flexibility, potentially benefiting creditors and suppliers.

Next Steps

• Closing of the merger transaction with ACELYRIN in the second quarter of 2025.
• Initiation of Phase 2 clinical trial of A-005 in multiple sclerosis in the second half of 2025.
• Finalizing the clinical development plan for Lonigutamab following the merger.
• Filing an Investigational New Drug Application for a third clinical candidate.
• Anticipating topline data from the Phase 3 program for ESK-001 in psoriasis in the first quarter of 2026.
• Anticipating topline data from the Phase 2b trial for ESK-001 in SLE in 2026.
• Anticipating topline data from the Phase 2 trial for A-005 in MS in 2026.

Key Dates

Keywords

Alumis, ACELYRIN, Merger, ESK-001, A-005, TYK2 inhibitor, Psoriasis, Multiple sclerosis, Clinical trials, Financial results, Biopharmaceutical, Immunology, Inflammation